1354952-94-5

Basic information

• Product Name: 3-(MethylaMino)cyclobutanol
• Synonyms: 3-(MethylaMino)cyclobutanol;3-(MethylaMino)cyclobutan-1-ol (cis/trans 5:1);3-(Methylamino)cyclobutan-1-ol;3-(Methylamino)cyclobutan-1-ol (cis/trans 5:1) - M10596
• CAS NO: 1354952-94-5
• Molecular Formula: C5H11NO
• Molecular Weight: 101.14694
• Mol File: 1354952-94-5.mol

Chemical Properties

• Boiling Point: 166.5±33.0 °C(Predicted)
• Appearance: /
• Density: 1.02±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 15.07±0.40(Predicted)
• CAS DataBase Reference: 3-(MethylaMino)cyclobutanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(MethylaMino)cyclobutanol(1354952-94-5)
• EPA Substance Registry System: 3-(MethylaMino)cyclobutanol(1354952-94-5)

Safety Data

• Hazardous Substances Data: 1354952-94-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(Methylamino)cyclobutanol is used as an intermediate in the synthesis of various organic compounds for pharmaceutical applications, leveraging its unique molecular structure to create new drugs or enhance existing ones.
Used in Chemical Industry:
3-(Methylamino)cyclobutanol is utilized as a building block in the chemical industry for the development of novel compounds and materials, taking advantage of its reactivity and structural features.
Potential Pharmacological Activities:
While further research is required, 3-(Methylamino)cyclobutanol may have potential pharmacological activities due to its molecular structure, suggesting possible uses in drug discovery and development.

Upstream product

• 389890-42-0 tert-butyl N-[(1r,3r)-3-hydroxycyclobutyl]carbamate 
• 154748-63-7 tert-butyl ((1s,3s)-3-hydroxycyclobutyl)carbamate 

Downstream Products

• 1392804-89-5 tert-butyl ((1r,3r)-3-hydroxycyclobutyl)(methyl)carbamate 

Relevant articles and documents

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

INHIBITORS OF THE TEC KINASE ENZYME FAMILY

The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.